The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-22 and is reviewed periodically as new material appears.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
By keeping a diary of blood glucose measurements and noting the effect of food and activity levels, individuals can modify their lifestyle to better control their diabetes. Studies suggest that the self-monitoring of blood glucose can improve HbA1c levels both in the short and long-term in patients with type 2 diabetes that are not on insulin. For individuals on insulin, glucose monitoring is also crucial in achieving effective dosing and timing.
Bradbury AF, Finnie MD, Smyth DG (1982). "Mechanism of C-terminal amide formation by pituitary enzymes". Nature. 298 (5875): 686–8. Bibcode:1982Natur.298..686B. doi:10.1038/298686a0. PMID 7099265. S2CID 4324776. Bradbury AF, Smyth DG (1987). "Enzyme-catalysed peptide amidation. Isolation of a stable intermediate formed by reaction of the amidating enzyme with an imino acid". Eur. J. Biochem. 169 (3): 579–84. doi:10.1111/j.1432-1033.1987.tb13648.x. PMID 3691506. Glembotski CC (1985). "Further characterization of the peptidyl alpha-amidating enzyme in rat anterior pituitary secretory granules". Arch. Biochem. Biophys. 241 (2): 673–83. doi:10.1016/0003-9861(85)90594-6. PMID 2994573. Katopodis AG, Ping D, May SW (1990). "A novel enzyme from bovine neurointermediate pituitary catalyzes dealkylation of alpha-hydroxyglycine derivatives, thereby functioning sequentially with peptidylglycine alpha-amidating monooxygenase in peptide amidation". Biochemistry. 29 (26): 6115–20. doi:10.1021/bi00478a001. PMID 2207061. Murthy AS, Keutmann HT, Eipper BA (1987). "Further characterization of peptidylglycine alpha-amidating monooxygenase from bovine neurointermediate pituitary". Mol. Endocrinol. 1 (4): 290–9. doi:10.1210/mend-1-4-290. PMID 3453894. Murthy AS, Mains RE, Eipper BA (1986). "Purification and characterization of peptidylglycine alpha-amidating monooxygenase from bovine neurointermediate pituitary". J. Biol. Chem. 261 (4): 1815–22. doi:10.1016/S0021-9258(17)36013-1. PMID 3944110.
=== Second generation === In 1976, 24-year-old Rich Snyder became the company president after his father's death. Along with his brother Guy, Rich had begun working in his father's In-N-Outs at an early age. Over the next 20 years, the chain experienced a period of rapid growth under Rich's leadership, expanding to 93 restaurants. In June 1988, In-N-Out opened its 50th location, in Thousand Palms, California. The first location outside of the Los Angeles metropolitan area opened in San Diego County in 1990, the 57th location in the chain. In 1992, In-N-Out opened its first non-Southern California restaurant, in Las Vegas, Nevada. Its first Northern California location opened the following year in Modesto. Expansion then spread to Northern California, including the San Francisco Bay Area, while additional Las Vegas-area restaurants were added. After opening the 93rd In-N-Out store in Fresno, California, on December 15, 1993, Rich Snyder and four other passengers died in a plane crash on approach to John Wayne Airport in Orange County, California. Upon Rich Snyder's death, Guy Snyder assumed the presidency in January 1994 and continued the company's aggressive expansion until he died from an overdose of painkillers in 1999. Under his leadership, In-N-Out's 100th location was opened in Gilroy, California, on November 10, 1994. He was president for nearly six years, expanding In-N-Out from 93 to 140 locations. His mother Esther subsequently took over the presidency.
Sources: en.wikipedia.org
Mixed ligand complexes are common for amino acids. Well known examples include [Co(en)2(glycinate)]2+, where en (ethylenediamine) is a spectator ligand. In the area of organometallic complexes, one example is the half-sandwich complex Cp*Ir(κ3-methionine).
The President directed other U.S. government agencies to put their technical assistance in developing countries under FOA's management as well. USDA in particular transferred OFAR's programs to FOA, while reconstituting the Foreign Agricultural Service for the task of building global markets for U.S. farm products. Administrative functions were consolidated as the various agencies came into FOA, and the Mutual Security Act of July 1953 instructed FOA to reduce personnel by at least 10% within 120 days. A large number of TCA's senior professionals were summarily dismissed, and FOA's administrator mounted an effort to compensate for lower U.S. government staffing by drawing on experts from U.S. universities and private voluntary organizations. The ExIm Bank's lending volume in developing countries was also cut dramatically in 1953. While a "trade not aid" strategy required the U.S. to import more goods from its allies, the administration was unable to convince Congress to liberalize import policy. On the contrary, the main foreign commercial measure taken at this time went in the other direction: the U.S. ramped up subsidies for exports of U.S. agricultural products. The 1953 amendment to the Mutual Security Act and the much larger Agricultural Trade Development and Assistance Act of 1954, known as "PL-480", allowed the U.S. government to buy U.S. farm surpluses and sell them in developing countries for inconvertible local currencies. Much of PL-480's foreign-currency revenue was returned to developing countries as a supplement to U.S. development assistance.
== Side effects == In studies, the most serious side effects of the combination olaratumab/doxorubicin were neutropenia (low count of neutrophil white blood cells) with a severity of grade 3 or 4 in 55% of patients, and musculoskeletal pain grade 3 or 4 in 8% of patients. Common milder side effects were lymphopenia, headache, diarrhoea, nausea and vomiting, mucositis, and reactions at the infusion site; all typical effects of cancer therapies.
Sources: en.wikipedia.org
Secondary U.S. sanctions prohibit any trading in U.S. dollars and prevent trade with a country, individuals, or organizations under the U.S. sanctions regime, affecting non-U.S. persons even where no U.S.-jurisdictional nexus existed. Primary sanctions, by contrast, restrict only U.S. companies, institutions, and citizens from doing business with sanctioned countries or entities. According to Rawi Abdelal, secondary sanctions often create friction between the U.S. and Europe because they reflect U.S. interference in the affairs and interests of the European Union (EU), and their increasing use is perceived in the EU as a violation of national and EU sovereignty. Secondary sanctions imposed on Iran and Russia are central to these tensions. Abdelal also argues that the U.S.'s overuse of sanctions risks gradual isolation and the continuing decline of U.S. influence in an emerging multipolar world. In June 2025, a majority of U.S. senators supported secondary sanctions against Russia that would impose 500% tariffs on countries that buy Russian oil, natural gas, uranium, and other exports. On July 31, 2025, the U.S. announced its first "secondary tariff," targeting India to penalize its trade with Russia, with Indian exports facing an extra 25% tariff beginning August 27, 2025.
The tissues of many animals respond to injury with inflammation, resulting in repair of the wound. Inflammation occurs in many taxa, but the nature of the response varies widely. In Hydra, a cnidarian, damage to the area around the mouth is fully healed within 20 minutes. Animals in several phyla, including annelids, arthropods, cnidaria, molluscs, nematodes, and vertebrates are able to produce antimicrobial peptides to fight off infection following an injury.
Thiobuscaline (TB), or 4-thiobuscaline (4-TB), also known as 3,5-dimethoxy-4-butylthiophenethylamine, is a psychoactive drug of the phenethylamine and scaline families related to the psychedelic drug mescaline. It is the analogue of buscaline in which the butoxy group at the 4 position has been replaced with a butylthio group. The drug is a non-hallucinogenic serotonin 5-HT2A receptor agonist with similar effects and potential uses to those of Ariadne.
=== Combination ESG and pharmacologic therapy === ESG can safely be combined with weight loss medications to improve weight loss or prevent weight regain after the procedure. The daily injectable medication liraglutide showed greater total body weight loss when combined with ESG compared to ESG alone at 7 months (approximately 25% vs 20% respectively). Similar results are anticipated with other incretin agents, such as semaglutide and tirzepatide, though no studies have directly assessed these combinations.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.